Advertisement: Mobas mid banner
Advertisement: Cambridge Network
ARM Innovation Hub
Advertisement: CPL mid banner
RealVNC mid-banner general
RealVNC mid banner careers
Advertisement: KISS
Advertisement: BKL
Advertisement: Barclays Eagle Labs
5 July, 2017 - 12:44 By Tony Quested

Mission Therapeutics packs first SAB with global heavyweights

Mission Therapeutics Jackson

Cambridge life science company Mission Therapeutics has formed its inaugural Scientific Advisory Board (SAB), bringing together an international group of big hitters.

Mission is a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat serious diseases including mitochondrial diseases, neurodegeneration, inflammation and cancer.

Co-founder and CSO, Professor Steve Jackson, will chair the SAB where he will be joined by four independent, internationally renowned scientists:-

  • Professor Sir Philip Cohen, Professor of Enzymology and deputy director of the Division of Signal Transduction Therapy, School of Life Sciences, University of Dundee, Scotland
  • Professor Patrick Chinnery, head of the Department of Clinical Neurosciences, University of Cambridge
  • Professor Jacob Corn, director at the Innovative Genomics Institute and assistant adjunct professor in the Department of Molecular and Cell Biology, University of California, Berkeley, USA
  • Professor Titia Sixma, group leader and head of Biochemistry Division at the Netherlands Cancer Institute, Professor at Erasmus MC Rotterdam, The Netherlands

Mission has built a leadership position and strength in the DUB field and the SAB will provide strategic advice to the company as it shapes and progresses its therapeutic programs and pipeline of first-in-class DUB inhibitors.

Dr Anker Lundemose, Mission’s CEO, said: “We have attracted a prestigious group of experts to our Scientific Advisory Board, where they bring a wealth of experience across, cell signalling, post-translational modifications, mitochondrial diseases, neurodegeneration and oncology.

“The formation of this board will help drive forward the clear clinical potential of our unique DUB platform for the production of first-in-class compounds targeting specific disease-associated DUBs for key indications where effective therapies are currently unavailable.

“The SAB members’ insights and guidance will prove invaluable as we prioritise and advance our programmes.”

• PHOTOGRAPH SHOWS: Professor Steve Jackson

Advertisement: Barclays Eagle Labs

Newsletter Subscription

Stay informed of the latest news and features